What is DSIP? What it does, benefits and what the evidence shows

DSIP (delta sleep-inducing peptide, also called emideltide) is a nine-amino-acid peptide that was named for its effect on the slow-wave "delta" rhythm in rabbit brain recordings, and it is sold today mainly as a sleep aid. We found no approval for it as a drug. The human evidence is a set of small studies, mostly from the 1980s and early 1990s, and it does not agree with itself: the early reports from the group that discovered the peptide were positive, while a later double-blind study in 16 chronic insomniacs concluded that DSIP was not likely to be of major therapeutic benefit. Nobody has established what DSIP does in natural sleep.

What DSIP is and how it works

DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. A Swiss group led by Schoenenberger and Monnier isolated it from the blood of rabbits and reported in 1977 that, when synthesized and infused into the brain ventricles of rabbits, it enhanced delta and spindle patterns on the EEG, while the shorter fragments and analogues they tested did not (Schoenenberger and Monnier, Proceedings of the National Academy of Sciences, 1977). A 1984 review described a broad list of other effects in animals and humans, including on hormone levels, neurotransmitters and circadian patterns, and noted that in cats the effect on REM sleep was more pronounced than on delta sleep (Graf and Kastin, Neuroscience & Biobehavioral Reviews, 1984).

The mechanism is the weak point. A 2006 mini-review in the Journal of Neurochemistry argued that the link between DSIP and sleep "has never been further characterized," in part because no DSIP gene, protein precursor or receptor had been found, and that the idea of DSIP as a sleep factor is "extremely poorly documented and still weak." The same authors noted that certain artificial analogues, but not DSIP itself, had shown slow-wave-sleep-promoting activity in their rabbit and rat work (Kovalzon and Strekalova, Journal of Neurochemistry, 2006). We found no newer paper that resolved this. So "delta sleep-inducing peptide" is best read as a name from 1977, not a proven job description.

Approval status

We found no approval for DSIP as a drug. We searched DailyMed (the U.S. label database) for emideltide, DSIP and "delta sleep-inducing peptide" and found no product label, and a ClinicalTrials.gov search turned up no study of it. We did not search the European Medicines Agency or other regulators' databases, so we can only speak for the U.S.

FDA's page on bulk drug substances that may present significant safety risks for compounding lists emideltide (DSIP) in a table of substances that were previously in "category 2" and were withdrawn by their nominators, so it is not in the active category 2 list on that page. The entry still carries FDA's reasoning: compounded drugs containing emideltide may pose a risk of immunogenicity for certain routes of administration and have complexities with peptide-related impurities and characterization, and FDA "has not identified safety-related information regarding emideltide for the proposed route of administration," so it lacks sufficient information to know whether the drug would cause harm in humans (FDA, page current as of April 22, 2026). At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted against recommending emideltide for the 503A bulks list, while recommending six other peptides including BPC-157 and Semax; the votes are non-binding (NCPA, July 31, 2026).

What people use it for

What the research actually shows

Sleep in insomniacs: positive early reports, weak later trial

The first reports came from the Basel group. In 6 middle-aged chronic insomniacs, an intravenous DSIP injection was followed by longer sleep with fewer interruptions and slightly more REM sleep, with no daytime sedation or other side effects reported; it was a small study of 6 people (Schneider-Helmert and Schoenenberger, Experientia, 1981). A 1984 summary by Schneider-Helmert of the group's insomnia work described improvement in sleep after single injections and, with repeated injections, normalization of sleep structure (Schneider-Helmert, European Neurology, 1984). An open study treated 7 patients with severe insomnia and reported normalized sleep in all but one, with the caveat that a long-standing drug habit could be a problem (Kaeser, European Neurology, 1984). An open study with no placebo group cannot separate a drug effect from expectation.

The most rigorous test we found was a double-blind, placebo-controlled study of 16 chronic insomniacs in a sleep laboratory. DSIP was given intravenously over several nights; polysomnography showed higher sleep efficiency and shorter time to fall asleep than placebo, but the authors judged the effects weak, said they could partly be due to an incidental change in the placebo group, and found no change in subjective sleep quality. Their conclusion was that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit (Bes et al., Neuropsychobiology, 1992). Note who wrote what: the strongly positive reports were co-authored by members of the group that discovered the peptide (Schoenenberger appears on several), and we found no large, independent replication.

Healthy volunteers

In six healthy volunteers in a double-blind crossover design, DSIP was reported to produce a feeling of sleep pressure and about 59% more total sleep than placebo over a window of roughly two hours after the infusion, followed by shorter time to fall asleep and better sleep efficiency the following night, without classic sedation and with no side effects observed (Schneider-Helmert et al., International Journal of Clinical Pharmacology, Therapy and Toxicology, 1981). That is six people, from the discovering group, in a single study.

Withdrawal from alcohol and opioids

A clinical group gave DSIP intravenously to 107 inpatients in withdrawal from alcohol (47) or opiates (60). Judged by physicians and nursing staff, symptoms disappeared or improved markedly in 97% of the opiate patients and 87% of the alcohol patients evaluated, though anxiety was slower to ease, and a few patients reported headaches (Dick et al., European Neurology, 1984). The report describes no control group and no blinding, and the assessment was clinical judgment, so it cannot show that DSIP caused the improvement. A later open opioid-detoxification study exists in the literature (Backmund et al., Journal of Clinical Psychopharmacology, 1998), but PubMed carries no abstract for it and we did not read the paper, so we are not describing its results.

Hormones: mostly nothing

Where DSIP was tested for hormone effects, the results were flat. In eight healthy women it did not change growth hormone or prolactin secretion (Giusti et al., Psychoneuroendocrinology, 1993), and in healthy men it did not change the ACTH and cortisol responses to CRH or a meal, which the authors said did not support an inhibitory role for DSIP on the stress axis (Späth-Schwalbe et al., Psychoneuroendocrinology, 1995).

Animal work on aging and stroke

Several research groups have published rodent studies of DSIP and a DSIP-containing preparation called Deltaran. In one, female mice given the preparation had a 24.1% longer maximum life span and about 2.6-fold fewer spontaneous tumors than saline controls, with no effect on mean life span (Popovich et al., Mechanisms of Ageing and Development, 2003). In rats after an induced stroke, motor performance recovered faster with DSIP, though the difference in brain infarct size was not significant (Tukhovskaya et al., Molecules, 2021). These are rodent findings from a small number of labs, and neither has been tested in people.

Everything else

We found no controlled human study of DSIP for weight loss, muscle recovery, mood, pain or anti-aging.

Side effects and risks

The old human studies reported few side effects, but they were small, supervised and short, and none was designed to find rare problems. One study did find a warning sign. In 24 women under general anesthesia, DSIP given as an intravenous bolus raised heart rate, reduced heart rate variability and, contrary to the researchers' hypothesis, made general anesthesia lighter rather than deeper on the bispectral index at the lowest dose studied; the authors concluded it probably reduced parasympathetic tone (Pomfrett et al., European Journal of Anaesthesiology, 2009). That is a very different result from "a gentle natural sleep peptide."

What we can say with the sources above:

• No long-term human safety data. The human studies span hours to days.
• Unresolved identity of the "active" agent. If the 2006 reviewers are right that DSIP-like activity may come from a different peptide, then studies of the synthetic nonapeptide may not describe what the name implies.
• FDA's stated gap. The agency said it had not identified safety-related information for the route it reviewed, and pointed to immunogenicity and impurity concerns for peptides of this type (see Approval status above).

What the lab tests show

As of September 30, 2026, VendorVerify's database has 10 DSIP vials from 6 vendors, drawn from 8 lab reports between February 2025 and August 2026. These are independent lab reports, and the breakdown below is a snapshot as of September 29, 2026, when 10 vials was a small sample, so a single vendor can move every number below.

• Purity. All 10 vials had a purity result; 9 were 99% or higher, the lowest was 98.98%, and the median was 99.72%.
• Amount vs. label. Overfill is the pattern: the median vial measured 16.8% over its label. Only 1 vial was within 5% of the label and 2 within 10%. Three vials were more than 20% over, and one of those was about 57% over.
• Failures. 1 of 10 vials failed our failure definition (empty, under 95% pure, more than 20% under label or more than 50% over). That was the roughly 57%-over vial.

So on these vials, purity looks fine and the weak spot is the amount in the vial, which can run well above what the label says. We can't draw conclusions about any vendor from a sample this size.

Because we don't have enough lab data on this compound to rank vendors for it, here are the highest-ranked vendors across all compounds right now. A vendor's overall record is a signal, not a guarantee for a compound they have never had tested.

Buying smarter

Check each vendor's full record, including how many reports sit behind the score and how recent they are, and look at the DSIP results page for what has been submitted for this compound. Treat a vendor-posted COA as a starting point (how to read a peptide COA, fake peptide COAs). With a compound this thinly documented, an independent identity, purity and quantity test on your own vial is worth paying for; how to get a peptide tested walks through it, and endotoxin in research peptides covers when to add that test.

If a report comes back with a fail, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify. People researching DSIP for sleep often also read about epitalon, selank and pinealon. Our peptide hub lists every compound we track, and what are grey market peptides explains the market itself.

Database figures without a date update automatically from VendorVerify's lab results; dated figures are snapshots. This isn't medical advice; DSIP is sold for research use only, and we found no approval for it as a drug.